drugset / Trial / NCT05621655
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
Phase 2
Active not recruiting
1512 enrolled
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the immunogenicity, safety and immune persistence of recombinant trivalent rotavirus subunit vaccine in healthy infants aged 6-12 weeks and healthy toddlers aged 7-71 months.
Timeline
- Start
- 2023-01-08
- Primary completion
- 2023-04-29
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Trivalent Subunit Rotavirus Vaccine | Vaccine | 60 ug | Intramuscular |
| Subject | Recombinant Trivalent Subunit Rotavirus Vaccine | Vaccine | 90 ug | Intramuscular |